Balyasny Asset Management’s Atrium Therapeutics RNA Stock Holding History
Bought
Maintained
Sold
Other funds holding RNA
Balyasny Asset Management's RNA Position: Q3 2026 in Review
Balyasny Asset Management reduced its Atrium Therapeutics (RNA) stake by 3.6% in Q3 2026, selling an estimated $45.2K and leaving 102,041 shares worth $845K. The position accounts for ﹤0.01% of the portfolio, ranked #2307.
Balyasny Asset Management first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. The position peaked at $3.14M in Q1 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.
- Balyasny Asset Management held 102,041 shares of Atrium Therapeutics worth $845K as of Q3 2026.
- Balyasny Asset Management sold 3,834 Atrium Therapeutics shares in Q3 2026, an estimated $45.2K.
- Atrium Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q3 2026, its #2307 holding.
- Balyasny Asset Management first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Balyasny Asset Management's Atrium Therapeutics position peaked at $3.14M in Q1 2026.
- 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.
Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.